COPD
MCID: PLM129
MIFTS: 74

Pulmonary Disease, Chronic Obstructive (COPD)

Categories: Respiratory diseases

Aliases & Classifications for Pulmonary Disease, Chronic Obstructive

MalaCards integrated aliases for Pulmonary Disease, Chronic Obstructive:

Name: Pulmonary Disease, Chronic Obstructive 57 76 75 44 38
Chronic Obstructive Pulmonary Disease 38 12 76 37 29 3 15 63
Copd 57 12 75 43 3 63
Chronic Obstructive Lung Disease 12 75 15
Pulmonary Disease, Chronic Obstructive, Severe Early-Onset 57 13
Pulmonary Disease, Chronic Obstructive, Susceptibility to 29 6
Chronic Obstructive Airway Disease 12 73
Pulmonary Disease, Obstructive, Chronic, Susceptibility to 40
Severe Early-Onset Chronic Obstructive Pulmonary Disease 75
Chronic Obstructive Pulmonary Disease of Horses 73
Pulmonary Disease Chronic Obstructive 55
Upper Respiratory Infections 73
Common Cold 73
Cold 12

Classifications:



External Ids:

OMIM 57 606963
Disease Ontology 12 DOID:3083
MeSH 44 D029424
NCIt 50 C3199
SNOMED-CT 68 13645005
KEGG 37 H01714

Summaries for Pulmonary Disease, Chronic Obstructive

MedlinePlus : 43 COPD (chronic obstructive pulmonary disease) makes it hard for you to breathe. The two main types are chronic bronchitis and emphysema. The main cause of COPD is long-term exposure to substances that irritate and damage the lungs. This is usually cigarette smoke. Air pollution, chemical fumes, or dust can also cause it. At first, COPD may cause no symptoms or only mild symptoms. As the disease gets worse, symptoms usually become more severe. They include A cough that produces a lot of mucus Shortness of breath, especially with physical activity Wheezing Chest tightness Doctors use lung function tests, imaging tests, and blood tests to diagnose COPD. There is no cure. Treatments may relieve symptoms. They include medicines, oxygen therapy, surgery, or a lung transplant. Quitting smoking is the most important step you can take to treat COPD. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pulmonary Disease, Chronic Obstructive, also known as chronic obstructive pulmonary disease, is related to respiratory failure and alpha-1-antitrypsin deficiency, and has symptoms including tremor, fever and angina pectoris. An important gene associated with Pulmonary Disease, Chronic Obstructive is LINC00229 (Long Intergenic Non-Protein Coding RNA 229), and among its related pathways/superpathways are Matrix Metalloproteinases and Rheumatoid arthritis. The drugs Advair and Anoro Ellipta have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotype is chronic obstructive pulmonary disease.

OMIM : 57 Chronic obstructive pulmonary disease (COPD) is a common, complex disorder associated with substantial morbidity and mortality. COPD is defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) (Silverman et al., 2002; Celedon et al., 2004). (606963)

UniProtKB/Swiss-Prot : 75 Pulmonary disease, chronic obstructive: A common, complex disorder defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC).

PubMed Health : 63 About chronic obstructive pulmonary disease: COPD, or chronic obstructive pulmonary (PULL-mun-ary) disease, is a progressive disease that makes it hard to breathe. "Progressive" means the disease gets worse over time.COPD can cause coughing that produces large amounts of mucus (a slimy substance), wheezing, shortness of breath, chest tightness, and other symptoms.Cigarette smoking is the leading cause of COPD. Most people who have COPD smoke or used to smoke. Long-term exposure to other lung irritants—such as air pollution, chemical fumes, or dust—also may contribute to COPD.

Wikipedia : 76 Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by... more...

Related Diseases for Pulmonary Disease, Chronic Obstructive

Diseases related to Pulmonary Disease, Chronic Obstructive via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 919)
# Related Disease Score Top Affiliating Genes
1 respiratory failure 32.9 CRP CXCL8 ELANE PDE4A SERPINA1 TNF
2 alpha-1-antitrypsin deficiency 32.8 CXCL8 ELANE SERPINA1
3 lung disease 32.6 ADRB2 CXCL8 ELANE HMOX1 PDE4A SERPINA1
4 meningitis 32.2 CRP CXCL8 TNF
5 proteasome-associated autoinflammatory syndrome 1 31.6 CRP CXCL8 ELANE PDE4A TNF
6 asthma 31.6 ADRB2 CXCL8 ELANE HDAC2 MMP1 PDE4A
7 bronchiectasis 31.2 CXCL8 ELANE SERPINA1
8 pneumonia 31.1 CRP CXCL8 ELANE TNF
9 pulmonary emphysema 30.9 ELANE HMOX1 MMP1 SERPINA1
10 aortic aneurysm, familial abdominal, 1 30.8 CRP ELANE MMP1
11 chlamydia 30.6 CRP CXCL8 TNF
12 sleep apnea 30.6 CRP CXCL8 TNF
13 acute respiratory distress syndrome 30.6 CXCL8 ELANE TNF
14 pulmonary fibrosis, idiopathic 30.6 CXCL8 ELANE MMP1 TNF
15 cystic fibrosis 30.5 ADRB2 CXCL8 ELANE SERPINA1
16 periodontal disease 30.5 CRP CXCL8 ELANE MMP1 TNF
17 vasculitis 30.4 CRP ELANE SERPINA1 TNF
18 pulpitis 30.3 CXCL8 MMP1 TNF
19 vascular disease 30.2 CRP ELANE HMOX1 TNF
20 bacterial pneumonia 30.2 CRP CXCL8 ELANE
21 pulmonary edema 30.2 CRP CXCL8 HMOX1 TNF
22 cystitis 30.2 CRP CXCL8 TNF
23 bronchiolitis 30.2 CRP CXCL8 TNF
24 bronchitis 30.2 CRP CXCL8 ELANE SERPINA1 TNF
25 gastroenteritis 30.1 CRP CXCL8 TNF
26 burns 30.1 CRP TNF
27 endocarditis 30.0 CRP CXCL8 TNF
28 pneumoconiosis 30.0 CXCL8 SERPINA1 TNF
29 severe acute respiratory syndrome 30.0 CRP CXCL8 TNF
30 myeloma, multiple 30.0 CRP CXCL8 MEG3 TNF TUG1
31 periodontitis 30.0 CRP CXCL8 MMP1 TNF
32 bacterial infectious disease 30.0 CRP CXCL8 ELANE TNF
33 atherosclerosis susceptibility 29.9 CRP TNF TUG1
34 brucellosis 29.8 CRP CXCL8 TNF
35 acute pancreatitis 29.7 CRP CXCL8 ELANE
36 bladder cancer 29.7 MEG3 SNHG5 TINCR TNF TUG1
37 inflammatory bowel disease 29.6 CRP CXCL8 ELANE MMP1 TNF
38 familial cold autoinflammatory syndrome 12.7
39 familial cold autoinflammatory syndrome 1 12.7
40 familial cold autoinflammatory syndrome 3 12.6
41 cold urticaria 12.5
42 cold agglutinin disease 12.5
43 crisponi/cold-induced sweating syndrome 1 12.5
44 paroxysmal cold hemoglobinuria 12.5
45 cold-induced sweating syndrome 12.5
46 familial cold autoinflammatory syndrome 4 12.5
47 familial cold autoinflammatory syndrome 2 12.4
48 crisponi/cold-induced sweating syndrome 2 12.4
49 crisponi/cold-induced sweating syndrome 3 12.4
50 cold-induced sweating syndrome including crisponi syndrome 12.1

Comorbidity relations with Pulmonary Disease, Chronic Obstructive via Phenotypic Disease Network (PDN):


Bronchitis Heart Disease

Graphical network of the top 20 diseases related to Pulmonary Disease, Chronic Obstructive:



Diseases related to Pulmonary Disease, Chronic Obstructive

Symptoms & Phenotypes for Pulmonary Disease, Chronic Obstructive

Clinical features from OMIM:

606963

Human phenotypes related to Pulmonary Disease, Chronic Obstructive:

32
# Description HPO Frequency HPO Source Accession
1 chronic obstructive pulmonary disease 32 HP:0006510

UMLS symptoms related to Pulmonary Disease, Chronic Obstructive:


tremor, fever, angina pectoris, pruritus, tinnitus, rhinorrhea, snoring, coughing, sore throat, vertigo/dizziness, equilibration disorder, catarrh, upper respiratory tract inflammation

Drugs & Therapeutics for Pulmonary Disease, Chronic Obstructive

PubMedHealth treatment related to Pulmonary Disease, Chronic Obstructive: 63

COPD has no cure yet. However, lifestyle changes and treatments can help you feel better, stay more active, and slow the progress of the disease.The goals of COPD treatment include:Relieving your symptomsSlowing the progress of the diseaseImproving your exercise tolerance (your ability to stay active)Preventing and treating complicationsImproving your overall healthTo assist with your treatment, your family doctor may advise you to see a pulmonologist. This is a doctor who specializes in treating lung disorders.

FDA approved drugs:

(show all 16)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Advair 18 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
2
Anoro Ellipta 18 UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE GlaxoSmithKline December of 2013
3
Arcapta 18 INDACATEROL MALEATE Novartis July 2011
4
Breo Ellipta 18 FLUTICASONE FUROATE; VILANTEROL TRIFENATATE GlaxoSmithKline May 2013
5
Brovana 18 ARFORMOTEROL TARTRATE Sepracor in October 2006
6
Daliresp 18 ROFLUMILAST Forest Pharmaceuticals February 2011
7
DuoNeb 18 ALBUTEROL SULFATE; IPRATROPIUM BROMIDE Dey Laboratories March 2001
8
Foradil Aerolizer 18 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
9
Incruse Ellipta 18 UMECLIDINIUM BROMIDE GlaxoSmithKline May 2014
10
Rayos 18 PREDNISONE Horizon Pharma July of 2012
11
Spiriva HandiHaler 18 TIOTROPIUM BROMIDE Boehringer Ingelheim February 2004
12
Stiolto Respimat 18 OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE Boehringer Ingelheim May 2015
13
Striverdi Respimat 18 OLODATEROL HYDROCHLORIDE Boehringer Ingelheim July 2014
14
Tudorza Pressair 18 ACLIDINIUM BROMIDE Forest Laboratories July 2012
15
Utibron Neohaler 18 GLYCOPYRROLATE ; INDACATEROL MALEATE Novartis October 2015
16
Xopenex 18 LEVALBUTEROL HYDROCHLORIDE Sepracor February 2002

Drugs for Pulmonary Disease, Chronic Obstructive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 689)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 83905-01-5 55185 447043
2
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
4
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90566-53-3 62924
5
Iloprost Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 78919-13-8 6443959
6 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
8
Terbutaline Approved Phase 4,Phase 3,Not Applicable 23031-25-6 5403
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
10
Metoprolol Approved, Investigational Phase 4,Phase 3,Not Applicable 37350-58-6, 51384-51-1 4171
11
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925
12
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51333-22-3 63006 5281004
13
Nitric Oxide Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 10102-43-9 145068
14
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
15
Mannitol Approved, Investigational Phase 4,Not Applicable 69-65-8 453 6251
16
Ipratropium Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60205-81-4, 22254-24-6 43232
17
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 564-25-0 54671203
18
Salmon Calcitonin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 47931-85-1 16129616
19
Tazobactam Approved Phase 4,Not Applicable 89786-04-9 123630
20
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
21
Clarithromycin Approved Phase 4,Phase 3 81103-11-9 84029
22
Cefuroxime Approved Phase 4,Phase 3 55268-75-2 5361202 5479529
23
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 354812-41-2, 151096-09-2 152946
24
Piperacillin Approved Phase 4,Not Applicable 66258-76-2 43672
25
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
26
Acetylcysteine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 616-91-1 12035
27
Theophylline Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-55-9 2153
28
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
29
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
30
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
31
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
32
Fenoterol Approved, Investigational Phase 4,Phase 3,Not Applicable 13392-18-2 3343
33
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
34
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
35
Procaterol Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 72332-33-3 688561
36
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 57-27-2 5288826
37 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 979-32-8
38
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 1 35189-28-7 6540478
39
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
40
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
41
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1 28014-46-2
42
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
43
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
44
Liraglutide Approved Phase 4 204656-20-2 44147092
45
Metformin Approved Phase 4,Early Phase 1 657-24-9 14219 4091
46 Olodaterol Approved Phase 4,Phase 3,Phase 2,Phase 1 868049-49-4
47
Adenosine Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 58-61-7 60961
48
Regadenoson Approved, Investigational Phase 4,Early Phase 1 313348-27-5 219024
49
Cortisone acetate Approved, Investigational Phase 4 1950-04-4, 50-04-4 5745
50
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7487-88-9 24083

Interventional clinical trials:

(show top 50) (show all 3366)
# Name Status NCT ID Phase Drugs
1 Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD) Unknown status NCT00132860 Phase 4 azithromycin
2 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
3 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
5 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
6 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
7 Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
8 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01116063 Phase 4 Inhaled iloprost
9 Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure Unknown status NCT02579200 Phase 4
10 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
11 The Role of Opinion Leaders in Enhancing Evidence-based Care After Chronic Obstructive Pulmonary Disease (COPD) Emergency Department (ED) Visits Unknown status NCT01107613 Phase 4
12 Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00288548 Phase 4 Metoprolol
13 Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
14 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4 Advair;Flovent
15 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
16 Small Airways Evaluation and Treatment Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
17 Strategy to Improve Adherence of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
18 Pulmonary Gas Exchange Response to Indacaterol in COPD Unknown status NCT02547558 Phase 4 Indacaterol
19 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
20 Simvastatin in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
21 Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD Unknown status NCT00860938 Phase 4 Budesonide
22 The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
23 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
24 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
25 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
26 Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep Unknown status NCT00731770 Phase 4 fluticasone/salmeterol 250/50;placebo
27 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
28 An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
29 EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
30 Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
31 Efficacy of Bronchial Thermoplasty in Korean Unknown status NCT02031263 Phase 4
32 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
33 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
34 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections Unknown status NCT02171338 Phase 4
35 Transfusion Strategies in Weaning Patients Unknown status NCT01256645 Phase 4
36 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
37 Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure. Unknown status NCT00331656 Phase 4
38 AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Unknown status NCT01460108 Phase 4
39 Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis Unknown status NCT02088216 Phase 4 N-acetylcysteine;Placebo
40 Surfactant Administration During Spontaneous Breathing Unknown status NCT01329432 Phase 4
41 Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO) Recruiting NCT03563001 Phase 4 Budesonide(160ug) and Formoterol(4.5ug) bid
42 Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease Recruiting NCT03551197 Phase 4 Budesonide and formoterol bid
43 A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00857766 Phase 4 ADVAIR DISKUS™ 250/50mcg
44 Effects of Liraglutide in Chronic Obstructive Pulmonary Disease Recruiting NCT03466021 Phase 4 Liraglutide;Placebo
45 Metformin in Chronic Obstructive Pulmonary Disease Completed NCT01247870 Phase 4 Metformin;Placebo
46 Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00984659 Phase 4 Fluticasone propionate/salmeterol combination product;Salmeterol;Placebo
47 Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00975195 Phase 4 tiotropium inhalation;salmeterol xinafoate;fluticasone propionate;placebo matched for fluticasone propionate
48 Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01397890 Phase 4 Budesonide/formoterol (Symbicort® Turbuhaler®);Tiotropium (SpirivaTM)
49 Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations Completed NCT00115492 Phase 4 Fluticasone Propionate/Salmeterol Combination Product;Salmeterol
50 ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies. Completed NCT00144911 Phase 4 Salmeterol;Fluticasone Propionate/Salmeterol Combination Product

Search NIH Clinical Center for Pulmonary Disease, Chronic Obstructive

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: pulmonary disease, chronic obstructive

Genetic Tests for Pulmonary Disease, Chronic Obstructive

Genetic tests related to Pulmonary Disease, Chronic Obstructive:

# Genetic test Affiliating Genes
1 Chronic Obstructive Pulmonary Disease 29 HMOX1 MMP1 SERPINA1
2 Pulmonary Disease, Chronic Obstructive, Susceptibility to 29

Anatomical Context for Pulmonary Disease, Chronic Obstructive

MalaCards organs/tissues related to Pulmonary Disease, Chronic Obstructive:

41
Lung, Testes, Heart, Neutrophil, Endothelial, Smooth Muscle, Bone

Publications for Pulmonary Disease, Chronic Obstructive

Articles related to Pulmonary Disease, Chronic Obstructive:

(show top 50) (show all 3769)
# Title Authors Year
1
The many faces of asthma-chronic obstructive pulmonary disease overlap. ( 30461532 )
2019
2
Improved quality of life associated with long-term use of guaifenesin in a patient with chronic obstructive pulmonary disease (COPD) & stable chronic bronchitis: A case report. ( 30450278 )
2019
3
Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure. ( 30132922 )
2019
4
Early readmission and mortality in acute exacerbation of chronic obstructive pulmonary disease with community-acquired pneumonia. ( 30428701 )
2019
5
The effect of comorbidity severity on pulmonary rehabilitation outcomes in chronic obstructive pulmonary disease patients. ( 30428708 )
2019
6
Pain in patients with chronic obstructive pulmonary disease indicated for post-acute pulmonary rehabilitation. ( 30428718 )
2019
7
Association of fine particulate matter on acute exacerbation of chronic obstructive pulmonary disease in Yancheng, China. ( 30273725 )
2019
8
Glottic patency during noninvasive ventilation in patients with chronic obstructive pulmonary disease. ( 30201317 )
2019
9
Exercise ventilatory inefficiency in heart failure and chronic obstructive pulmonary disease. ( 30201380 )
2019
10
Glottic patency during noninvasive ventilation in patients with chronic obstructive pulmonary disease. ( 30026086 )
2019
11
Pulmonary rehabilitation and BDNF levels in patients with chronic obstructive pulmonary disease: A pilot study. ( 30067940 )
2019
12
Federal Weatherization and Health Education Team up: Process Evaluation of a New Strategy to Improve Health Equity for People With Asthma and Chronic Obstructive Pulmonary Disease. ( 29595574 )
2019
13
Adherence to long-term oxygen therapy in patients with chronic obstructive pulmonary disease. ( 29631423 )
2019
14
Prospective risk of osteoporotic fractures in patients with advanced chronic obstructive pulmonary disease. ( 29661041 )
2019
15
MiR-3202 protects smokers from chronic obstructive pulmonary disease through inhibiting FAIM2: An in vivo and in vitro study. ( 29208459 )
2018
16
Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease. ( 29295966 )
2018
17
Association between Genetic Variations of MERTK and Chronic Obstructive Pulmonary Disease in Koreans. ( 29359540 )
2018
18
Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease: A Focus on Right Ventricular (Dys)Function. ( 29966637 )
2018
19
COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. ( 29443332 )
2018
20
Emphysematous and Nonemphysematous Gas Trapping in Chronic Obstructive Pulmonary Disease: Quantitative CT Findings and Pulmonary Function. ( 29361243 )
2018
21
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. ( 29331313 )
2018
22
Chronic Obstructive Pulmonary Disease Exacerbations Are Influenced by Gastroesophageal Reflux Disease. ( 29428028 )
2018
23
Chronic obstructive pulmonary disease-induced autonomic dysfunction may be associated with cerebral blood flow regulation and brain function. ( 29978508 )
2018
24
Perception and Awareness of chronic obstructive pulmonary disease, Chronic Bronchitis and Pulmonary Emphysema in the Spanish Urban Population. ( 29428681 )
2018
25
A Comparison of Pain, Fatigue, Dyspnea and their Impact on Quality of Life in Pulmonary Rehabilitation Participants with Chronic Obstructive Pulmonary Disease. ( 29227712 )
2018
26
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. ( 29159953 )
2018
27
Effectiveness of a respiratory rehabilitation programme in patients with chronic obstructive pulmonary disease. ( 29287828 )
2018
28
Features of Chronic Obstructive Pulmonary Disease as Predictors of Lung Cancer. ( 29452098 )
2018
29
Pulmonary Embolism Among Patients With Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: Implications For Emergency Medicine. ( 29945817 )
2018
30
Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis. ( 29915333 )
2018
31
Ventilator-dependent pulmonary nocardiosis in a patient with chronic obstructive pulmonary disease. ( 29319037 )
2018
32
Major Depression in Long-Term Oxygen Therapy Dependent Chronic Obstructive Pulmonary Disease. ( 27220917 )
2018
33
Significance of Low-Attenuation Cluster Analysis on Quantitative CT in the Evaluation of Chronic Obstructive Pulmonary Disease. ( 29354010 )
2018
34
Whole-genome methylation profiling of peripheral blood mononuclear cell for acute exacerbations of chronic obstructive pulmonary disease treated with corticosteroid. ( 29329142 )
2018
35
An exploration of pain experiences and their meaning in people with chronic obstructive pulmonary disease. ( 29319390 )
2018
36
Self-management strategies in chronic obstructive pulmonary disease: a first step toward personalized medicine. ( 29278544 )
2018
37
What Can We Apply to Manage Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Acute Respiratory Failure? ( 29372630 )
2018
38
Linear rheology as a potential monitoring tool for sputum in patients with Chronic Obstructive Pulmonary Disease (COPD). ( 29278868 )
2018
39
Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. ( 29254748 )
2018
40
Gastroesophageal reflux symptoms and nasal symptoms affect the severity of bronchitis symptoms in patients with chronic obstructive pulmonary disease. ( 29773294 )
2018
41
Comparative analysis of salivary sialic acid levels in patients with chronic obstructive pulmonary disease and chronic periodontitis patients: A biochemical study. ( 29442082 )
2018
42
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. ( 28987804 )
2018
43
Study of inflammatory markers and BODE index in chronic obstructive pulmonary disease. ( 29319032 )
2018
44
Effects of telephone support on exercise capacity and quality of life in patients with chronic obstructive pulmonary disease: a meta-analysis. ( 29320895 )
2018
45
"At First I Couldn't Catch My Breath": Process and Strategies for Managing Chronic Obstructive Pulmonary Disease. ( 29214821 )
2018
46
Unpredictable episodic breathlessness in patients with advanced chronic obstructive pulmonary disease and lung cancer: a qualitative study. ( 29046956 )
2018
47
Cost-effectiveness of FreeO<sub>2</sub>in patients with chronic obstructive pulmonary disease hospitalised for acute exacerbations: analysis of a pilot study in Quebec. ( 29362258 )
2018
48
Obesity and Severity of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. ( 29053337 )
2018
49
Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. ( 29180527 )
2018
50
Counseling intervention to improve quality of life in patients with pre-existing acute myocardial infarction (AMI) or chronic obstructive pulmonary disease (COPD): a pilot study. ( 30083623 )
2018